Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 912.64
ACHN's Cash to Debt is ranked higher than
57% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. ACHN: 912.64 )
Ranked among companies with meaningful Cash to Debt only.
ACHN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 117.70 Max: No Debt
Current: 912.64
Equity to Asset 0.90
ACHN's Equity to Asset is ranked higher than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACHN: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
ACHN' s Equity to Asset Range Over the Past 10 Years
Min: -6.98  Med: 0.65 Max: 0.91
Current: 0.9
-6.98
0.91
F-Score: 4
Z-Score: 10.56
M-Score: 255.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -154.26
ACHN's Operating margin (%) is ranked lower than
58% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. ACHN: -154.26 )
Ranked among companies with meaningful Operating margin (%) only.
ACHN' s Operating margin (%) Range Over the Past 10 Years
Min: -17954.25  Med: -747.67 Max: 11879.49
Current: -154.26
-17954.25
11879.49
Net-margin (%) -126.20
ACHN's Net-margin (%) is ranked lower than
57% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. ACHN: -126.20 )
Ranked among companies with meaningful Net-margin (%) only.
ACHN' s Net-margin (%) Range Over the Past 10 Years
Min: -17897.17  Med: -713.80 Max: 12030.34
Current: -126.2
-17897.17
12030.34
ROE (%) -18.15
ACHN's ROE (%) is ranked higher than
60% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. ACHN: -18.15 )
Ranked among companies with meaningful ROE (%) only.
ACHN' s ROE (%) Range Over the Past 10 Years
Min: -199.15  Med: -77.16 Max: -46.56
Current: -18.15
-199.15
-46.56
ROA (%) -16.60
ACHN's ROA (%) is ranked higher than
60% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. ACHN: -16.60 )
Ranked among companies with meaningful ROA (%) only.
ACHN' s ROA (%) Range Over the Past 10 Years
Min: -103.25  Med: -61.16 Max: -43.23
Current: -16.6
-103.25
-43.23
ROC (Joel Greenblatt) (%) -2479.55
ACHN's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. ACHN: -2479.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACHN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6041.18  Med: -2847.52 Max: -457.53
Current: -2479.55
-6041.18
-457.53
EBITDA Growth (3Y)(%) 1.00
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. ACHN: 1.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACHN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -40.95 Max: 4.1
Current: 1
0
4.1
EPS Growth (3Y)(%) 0.70
ACHN's EPS Growth (3Y)(%) is ranked higher than
57% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. ACHN: 0.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACHN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.5  Med: -26.80 Max: 3.5
Current: 0.7
-65.5
3.5
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

ACHN Guru Trades in Q4 2014

John Burbank 36,104 sh (New)
John Burbank 207,000 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
Steven Cohen 621,900 sh (-40.66%)
Paul Tudor Jones 13,942 sh (-69.17%)
» More
Q1 2015

ACHN Guru Trades in Q1 2015

John Burbank Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q2 2015

ACHN Guru Trades in Q2 2015

Steven Cohen 8,388,200 sh (New)
Paul Tudor Jones 10,400 sh (New)
» More
Q3 2015

ACHN Guru Trades in Q3 2015

Steven Cohen 9,772,018 sh (+16.50%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 49.75
ACHN's Forward P/E is ranked lower than
88% of the 347 Companies
in the Global Biotechnology industry.

( Industry Median: 16.47 vs. ACHN: 49.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.89
ACHN's P/B is ranked higher than
70% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. ACHN: 1.89 )
Ranked among companies with meaningful P/B only.
ACHN' s P/B Range Over the Past 10 Years
Min: 0.79  Med: 3.80 Max: 17.77
Current: 1.89
0.79
17.77
P/S 19.98
ACHN's P/S is ranked lower than
69% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. ACHN: 19.98 )
Ranked among companies with meaningful P/S only.
ACHN' s P/S Range Over the Past 10 Years
Min: 0.78  Med: 137.75 Max: 943
Current: 19.98
0.78
943
Current Ratio 9.40
ACHN's Current Ratio is ranked higher than
73% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. ACHN: 9.40 )
Ranked among companies with meaningful Current Ratio only.
ACHN' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.22 Max: 19.64
Current: 9.4
1.06
19.64
Quick Ratio 9.40
ACHN's Quick Ratio is ranked higher than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. ACHN: 9.40 )
Ranked among companies with meaningful Quick Ratio only.
ACHN' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.22 Max: 19.64
Current: 9.4
1.06
19.64
Days Sales Outstanding 4.00
ACHN's Days Sales Outstanding is ranked higher than
95% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. ACHN: 4.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACHN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.29  Med: 62.56 Max: 152.21
Current: 4
12.29
152.21

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.96
ACHN's Price/Net Cash is ranked higher than
82% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 5.81 vs. ACHN: 1.96 )
Ranked among companies with meaningful Price/Net Cash only.
ACHN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.82  Med: 5.75 Max: 12.7
Current: 1.96
0.82
12.7
Price/Net Current Asset Value 1.95
ACHN's Price/Net Current Asset Value is ranked higher than
81% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 5.14 vs. ACHN: 1.95 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACHN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.78  Med: 5.09 Max: 12.29
Current: 1.95
0.78
12.29
Price/Tangible Book 1.88
ACHN's Price/Tangible Book is ranked higher than
77% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 3.93 vs. ACHN: 1.88 )
Ranked among companies with meaningful Price/Tangible Book only.
ACHN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.72  Med: 4.35 Max: 77.75
Current: 1.88
0.72
77.75
Price/Projected FCF 28.19
ACHN's Price/Projected FCF is ranked lower than
91% of the 296 Companies
in the Global Biotechnology industry.

( Industry Median: 3.14 vs. ACHN: 28.19 )
Ranked among companies with meaningful Price/Projected FCF only.
ACHN' s Price/Projected FCF Range Over the Past 10 Years
Min: 32.9  Med: 32.90 Max: 32.9
Current: 28.19
Price/Median PS Value 0.17
ACHN's Price/Median PS Value is ranked higher than
93% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. ACHN: 0.17 )
Ranked among companies with meaningful Price/Median PS Value only.
ACHN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 1.00 Max: 6.42
Current: 0.17
0.01
6.42
Earnings Yield (Greenblatt) (%) -12.52
ACHN's Earnings Yield (Greenblatt) (%) is ranked lower than
58% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. ACHN: -12.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ACHN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -12.77  Med: 502.95 Max: 2697.4
Current: -12.52
-12.77
2697.4

More Statistics

Revenue(Mil) $37
EPS $ -0.45
Beta2.11
Short Percentage of Float16.32%
52-Week Range $5.67 - 12.94
Shares Outstanding(Mil)136.54

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 66 38 75 200
EPS($) -0.11 -0.14 0.12 1.17
EPS without NRI($) -0.11 -0.14 0.12 1.17

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
Early Briefing on Biotechnology Stocks -- Achillion Pharma, CTI BioPharma, Inovio Pharma, and Keryx... Feb 10 2016
Achillion to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 08 2016
Achillion Announces Appointments of Martha Manning as General Counsel and Amy Jennings as Head of... Feb 03 2016
Achillion Pharma downgraded by Leerink Partners Jan 29 2016
Zacks.com featured expert Kevin Matras highlights: Achillion Pharmaceuticals, Opko Health, Global... Jan 27 2016
A Company's First Profit Can Mean Big Profits to Investors Jan 26 2016
Bulls are playing for Achillion rebound Jan 15 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 8,... Jan 08 2016
Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer Jan 04 2016
Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer Jan 04 2016
4 stocks to watch Dec 31 2015
Achillion (ACHN): Moving Average Crossover Alert Dec 31 2015
Unusual activity in AAL, ACHN Dec 30 2015
Bristol-Myers Inks Deal to Sell HIV Pipeline to ViiV Healthcare Dec 21 2015
Strength Seen in Sequenom (SQNM): Stock Jumps 5% in Session Dec 21 2015
Today's Market Driven by Key Factors -- Research on Tumi Holdings, Meritor, Achillion... Dec 21 2015
Achillion Appoints Dr. Frank Verwiel to Board of Directors Dec 16 2015
Achillion Appoints Dr. Frank Verwiel to Board of Directors Dec 16 2015
The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, BJ's Restaurants, Isle of Capri... Dec 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK